Stefan Müller-Hülsbeck

Stefan Müller-Hülsbeck

Auto-generated profile, based on publicly available information

Stefan Müller-Hülsbeck

Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie, DIAKO Krankenhaus gGmbH Flensburg Germany

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2014 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
JLJohannes Lammer
Johannes Lammer
TZThomas Zeller
Thomas Zeller
KHKlaus A. Hausegger
Klaus A. Hausegger
PSPhilipp J. Schaefer
Philipp J. Schaefer
MGManfred Gschwendtner
Manfred Gschwendtner
MSMaria Schoder
Maria Schoder

22 November 2020 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
SMStefan Müller-Hülsbeck
Stefan Müller-Hülsbeck
ABAndrew Benko
Andrew Benko
YSYoshimitsu Soga
Yoshimitsu Soga
MFMasahiko Fujihara
Masahiko Fujihara
OIOsamu Iida
Osamu Iida
WGWilliam A. Gray
William A. Gray

9 July 2016 in Journal of Endovascular Therapy
Verified
Journal Article
Open access
SMStefan Müller-Hülsbeck
Stefan Müller-Hülsbeck
KKKoen Keirse
Koen Keirse
TZThomas Zeller
Thomas Zeller
HSHerman Schroë
Herman Schroë
JDJuan Diaz-Cartelle
Juan Diaz-Cartelle
Purpose: To report the 12-month results of the MAJESTIC clinical study of the self-expanding Eluvia paclitaxel-eluting stent in the treatment of femoropopliteal lesions. Methods: The prospective, single-arm, multicenter trial (clinicaltrials.gov identifier NCT01820637) enrolled 57 patients (mean age 69±9 years; 47 men) with chronic lower limb ischemia referable to de novo or restenotic lesions in the native superficial femoral and/or proximal popliteal arteries. A third of the patients had diabetes. Mean lesion length was 70.8±28.1 mm, and diameter stenosis was 86.3%±16.2%; 26 (46%) lesions were occluded. Primary patency was defined as duplex ultrasound peak systolic velocity ratio ≤2.5 and the absence of target lesion revascularization (TLR) or bypass. Major adverse events (MAEs) included all-cause death through 1 month and target limb major amputation and TLR through 12 months. Results: All 57 patients had a single Eluvia stent implanted, employing pre- and postdilation in 93% (53/57) and 95% (54/57) of cases, respectively. Technical success was 97% (55/57; 2 failures due to residual stenosis >30%). At 12 months, primary patency was 96% (49/51) and the MAE rate was 4% (2/53); both MAEs were TLRs. No stent fractures were identified. There were no major amputations. One death occurred 368 days postprocedure, unrelated to the device or procedure. Improvements in the Rutherford category were sustained through 1 year, with 81% (43/53) exhibiting no symptoms (category 0) and 13% (7/53) presenting with mild claudication (category 1). Mean ABI improved from 0.73±0.22 at baseline to 1.02±0.20 at 12 months. Conclusion: MAJESTIC results showed that patients whose femoropopliteal arteries were treated with the Eluvia drug-eluting stent sustained high patency and low MAE rates through 12 months.

25 September 2017 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
SMStefan Müller-Hülsbeck
Stefan Müller-Hülsbeck
KKKoen Keirse
Koen Keirse
TZThomas Zeller
Thomas Zeller
HSHerman Schroë
Herman Schroë
JDJuan Diaz-Cartelle
Juan Diaz-Cartelle

9 February 2016 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
DTDimitrios Tsetis
Dimitrios Tsetis
RURaman Uberoi
Raman Uberoi
FFFabrizio Fanelli
Fabrizio Fanelli
IRIain Roberston
Iain Roberston
MKMiltiadis Krokidis
Miltiadis Krokidis
ABAnna Maria Belli
Anna Maria Belli

1 December 2010 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
PDF file
SMStefan Müller-Hülsbeck
Stefan Müller-Hülsbeck
PSPhilipp J. Schäfer
Philipp J. Schäfer
NCNikolas Charalambous
Nikolas Charalambous
HYHiroshi Yagi
Hiroshi Yagi
MHMartin Heller
Martin Heller
TJThomas Jahnke
Thomas Jahnke
Purpose: To examine and compare in an ex vivo study different nitinol stent designs intended for the superficial femoral artery (SFA) with regard to the appearance of fracture. Methods: Seven different 8-x40-mm nitinol stents were evaluated (Misago, Absolute, Smart, Luminexx, Sentinol, Lifestent NT, and Sinus-Superflex). Finite element analysis (FEA) was used for digitalized stent design comparison; the strain during stent movement was calculated for bending, compression, and torsion. Additional mechanical fatigue tests for bending (70°), compression (40%), and torsion (twisted counterclockwise by 180°) were performed up to 650,000 cycles or until a fracture was observed. Results: The FEA bending test showed that only the Misago, LifeStent, and Absolute stents presented no zones of high strain; in the torsion test, the Smart stent also had no zones of high strain. Macroscopic evaluation after mechanical bending indicated that the LifeStent performed the best (no stent fracture after 650,000 cycles). Misago and Absolute stents showed fractures at 536,000 cycles and 456,667 cycles, respectively (range 320,000–650,000 cycles). After compression and torsion testing, Misago showed no stent fracture after 650,000 cycles. The worst performing stent was Luminexx during all test cycles. Conclusion: The 7 SFA stents showed differences in the incidence of high strain zones, which indicates a potential for stent fracture, as demonstrated by the mechanical fatigue tests. Differences in stent design might play a major role in the appearance of stent strut fracture related to restenosis and reocclusion.